Clinical trial · Observational
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma: a Multicenter, Non-interventional, Retrospective Survey
NCT01441661CI-TRIAL-00009748completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase knowledge about usage, dosage, efficacy and safety under conditions of routine use of Sunitinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Sunitinib Renal Cell Carcinoma
- description
- Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
Primary outcomes (1)
- measure
- Disease control rate (DCR)
- timeFrame
- 2008-2011 (up to 3 years)
- description
- * To determine the Disease control rate (DCR) defined as the percentage of patients who have a partial response (CR) or complete response (PR) to Sunitinib plus those whose disease is stable (DS). * To determine the Objective Responsive Rate (ORR) defined as the percentage of patients who have a partial response (PR) or complete response (CR) to Sunitinib.
Secondary outcomes (3)
- measure
- Progression Free survival (PFS)
- timeFrame
- 2008 - 2011 (up to 3 years)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed, unresectable advanced renal cell carcinoma; * Sunitinib as first-line treatment alone or combined with other therapies. Exclusion Criteria: * History of Grade 3/4 severe allergic reaction to Sunitinib or its metabolites
References
Publications (0)
Data not yet available
No reference posted for this study.